bisulfite sequencing

This Week in PLOS

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

The team demonstrated that the approach can yield high sensitivity while maintaining near-perfect specificity, but it must now replicate the early results in a much larger study.

Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more. 

The Epigenetics For Female Personalised Cancer Care (EpiFemCare) project recently published its findings in two papers in the journal Genome Medicine.

Investigators identified mutation, expression, and methylation differences in colorectal polyps from individuals with or without colorectal cancer.

The companies will integrate Cambridge's TrueMethyl technology for oxidative bisulfite sequencing with NuGen's sequencing library preparation kits.

Investigators identified changes in methylation at neurobiology-related genes when comparing blood methylation in twin pairs discordant for ALS.

This Week in Cell

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

Results from up to eight stages of mouse or human retina development highlight the importance of histone modifications and other epigenetic shifts during differentiation.

Pages

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.